Literature DB >> 12675527

A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics.

Giuseppe Musumarra1, Vincenza Barresi, Daniele F Condorelli, Salvatore Scirè.   

Abstract

A multivariate analysis of the National Cancer Institute gene expression database is reported here. The soft independent modelling of a class analogy approach achieved cell line classification according to histological origin. With the PCA method, based on the expression of 9605 genes and ESTs, classification of colon, leukaemia, renal, melanoma and CNS cells could be performed, but not of lung, breast and ovarian cells. Another multivariate procedure, called partial least squares discriminant analysis (PLS-DA), provides bioinformatic clues for the selection of a limited number of gene transcripts most effective in discriminating different tumoral histotypes. Among them it is possible to identify candidates in the development of new diagnostic tests for cancer detection and unknown genes deserving high priority in further studies. In particular, melan-A, acid phosphatase 5, dopachrome tautomerase, S100-beta and acid ceramidase were found to be among the most important genes for melanoma. The potential of the present bioinformatic approach is exemplified by its ability to identify differentiation and diagnostic markers already in use in clinical settings, such as protein S-100, a prognostic parameter in patients with metastatic melanoma and a screening marker for melanoma metastasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675527     DOI: 10.1515/BC.2003.037

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  25 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  Discovery and evaluation of inhibitors of human ceramidase.

Authors:  Jeremiah M Draper; Zuping Xia; Ryan A Smith; Yan Zhuang; Wenxue Wang; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

Review 3.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

4.  Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine.

Authors:  Carmen Bedia; Josefina Casas; Nathalie Andrieu-Abadie; Gemma Fabriàs; Thierry Levade
Journal:  J Biol Chem       Date:  2011-06-23       Impact factor: 5.157

5.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

Review 6.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

7.  Improved synthesis of a fluorogenic ceramidase substrate.

Authors:  Zuping Xia; Jeremiah M Draper; Charles D Smith
Journal:  Bioorg Med Chem       Date:  2010-01-06       Impact factor: 3.641

8.  Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets.

Authors:  Yehia Mechref; Ahmed Hussein; Slavka Bekesova; Vitara Pungpapong; Min Zhang; Lacey E Dobrolecki; Robert J Hickey; Zane T Hammoud; Milos V Novotny
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

9.  Potent inhibition of Acid ceramidase by novel B-13 analogues.

Authors:  Denny Proksch; Jan Jasper Klein; Christoph Arenz
Journal:  J Lipids       Date:  2010-12-09

Review 10.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.